Analysis of mechanisms of free-energy coupling and uncoupling by inhibitor titrations: theory, computer modeling and experiments.
The rates of ATP synthesis and of ATP-driven NAD reduction have been measured in bovine heart submitochondrial particles as a function of the fraction of inhibited redox pumps (in titrations with either antimycin or rotenone) and of the fraction of inhibited ATPases (in titrations with DCCD). The flux control coefficients of the redox and ATPase proton pumps on the rates of ATP synthesis and of ATP-driven NAD reduction have been derived and found to be equal to 1 for both pumps; i.e., both pumps appear to be 'completely rate limiting'. A theoretical analysis of the inhibitor titration approach based on kinetic models of chemiosmotic coupling and on the theory of metabolic control is presented. This analysis (i) shows that the results of the single inhibitor titrations are incompatible with a delocalized chemiosmotic mechanism of energy coupling if the proton conductance of the membrane is sufficiently low with respect to the conductances of the pumps; and (ii) suggests an experimental approach based on the determination of the P/O and the respiratory control ratios at different degrees of inhibition of the proton pumps to establish the origin of the 'loose coupling' of submitochondrial particle preparations. Three independent types of observation show that the 'loose coupling' of the particle preparation is not mainly due to an increased membrane proton conductance. The same and other independent observations are consistent with the view that the loose coupling of submitochondrial particle preparation is due mainly to inhomogeneity, i.e. to the presence of a subpopulation of highly leaky non-phosphorylating vesicles respiring at maximal rate. The results as a whole together with the simulations and analysis presented lead to the conclusion that the mechanism of free-energy coupling in submitochondrial particles is not completely delocalized.
D000251:Adenosine Triphosphatases; D000255:Adenosine Triphosphate / Q000096:biosynthesis / Q000378:metabolism; D000818:Animals; D000968:Antimycin A / Q000031:analogs & derivatives / Q000494:pharmacology; D016227:Benzoquinones; D002417:Cattle; D003198:Computer Simulation; D004024:Dicyclohexylcarbodiimide / Q000494:pharmacology; D004734:Energy Metabolism; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008929:Mitochondria, Heart / Q000187:drug effects / Q000378:metabolism*; D008954:Models, Biological; D009243:NAD / Q000378:metabolism; D010084:Oxidation-Reduction; D010101:Oxygen Consumption; D010758:Phosphorus / Q000378:metabolism; D011522:Protons; D011809:Quinones / Q000378:metabolism; D012402:Rotenone / Q000494:pharmacology; D013367:Submitochondrial Particles / Q000187:drug effects / Q000378:metabolism*; D013816:Thermodynamics
D016227:Benzoquinones; D007473:Ion Channels; D011522:Protons; D011809:Quinones; D012402:Rotenone; D009243:NAD; C032456:antimycin; D010758:Phosphorus; D004024:Dicyclohexylcarbodiimide; D000968:Antimycin A; D000255:Adenosine Triphosphate; D000251:Adenosine Triphosphatases; C034257:duroquinone